| (Values in U.S. Thousands) | Sep, 2024 | Sep, 2023 | Sep, 2022 | Sep, 2021 | Sep, 2020 |
| Sales | 20,178,000 | 19,372,000 | 18,870,000 | 20,248,000 | 17,117,000 |
| Sales Growth | +4.16% | +2.66% | -6.81% | +18.29% | -1.00% |
| Net Income | 1,705,000 | 1,484,000 | 1,779,000 | 2,092,000 | 874,000 |
| Net Income Growth | +14.89% | -16.58% | -14.96% | +139.36% | -29.12% |
Becton Dickinson and Company (BDX)
227.50 x 1 229.80 x 1
Pre-market by (Cboe BZX)
228.71 +0.71 (+0.31%) 03/27/25 [NYSE]
227.50 x 1 229.80 x 1
Pre-market 229.09 +0.38 (+0.17%) 19:00 ET
for Thu, Mar 27th, 2025
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
Fiscal Year End Date: 09/30